|MDACC Study No:||CERN09-02 (clinicaltrials.gov NCT No: NCT01295944)|
|Title:||Phase II trial of carboplatin and bevacizumab for the treatment of recurrent low-grade and anaplastic supratentorial, infratentorial and spinal cord ependymoma in adults|
|Principal Investigator:||Mark R. Gilbert|
|Treatment Agent:||Bevacizumab; Carboplatin|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
bevacizumab and carboplatin can help to control recurrent ependymoma. The
safety of this drug combination will also be studied.